

## DAFTAR PUSTAKA

1. Bajwa, H., Basit, H. (2023). Thalassemia. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; Available from: <https://www.ncbi.nlm.nih.gov/books/NBK545151/>
2. Wahidiyat, P. A., Iskandar, S. D. & Sekarsari, D. (2018). Evaluasi Kelebihan Zat Besi Antar Kelompok Umur Menggunakan Pencitraan Resonansi Magnetik dan Korelasinya dengan Profil Zat Besi pada Thalassemia yang Bergantung pada Transfusi. s.l.:Acta Medica Indonesiana The Indonesian Journal of Internal Medicine
3. Mavrogeni, S.(2012). Comparasion of myocardial and hepatic iron loading, assessed by MRI T2\*, in patients with myelodysplastic syndromes, thalassemia major and controls.. Blood Transfusion, p. 237
4. Mishra, A. K. & Tiwari, A. (2013). Iron Overload in Beta Thalassaemia Major and Intermedia Patients. Bhopal: Maedica a journal of clinical medicine.
5. Musallam, K. M. et al. (2011). Elevated liver iron concentration is a marker of increased morbidity in patients with beta-thalassemia intermedia. haematologica
6. Puar, N., Newell, B., Shao, L. (2019). Blueberry Muffin Skin Lesions in an Infant With Epsilon Gamma Delta Beta Thalassemia. Pediatr Dev Pathol. 2019 Nov-Dec;22(6):599-600
7. Raief Mosaad, B.M., Ibrahim, A.S., Mansour, M.G., ElAlfy, M.S., Ebeid, F.S.E., Jeldayem, E.H. (2022). The role of MRI-R2\* in the detection of subclinical hepatocytic iron loading among transfusion-dependent sickle cell disease patients and correlation with hepatic and cardiac iron loading. Insights Imaging;13(1):140. doi: 10.1186/s13244-022-01280-x



8. Alves de Assisa, R. Feitosa Ribeiroa, A.A., Kayb, F.U., Rosembergb, L.A., Nomurab, C.H., Loggettoc, S.R., Araujod, A.S., Juniore, A.F., Almeida Veríssimof, M.P., Baldanzig, G.R., Espósitoh, B.P., Baronib, R.H., Woodi, J.C., Hamerschlak, N. (2012). Pancreatic iron stores assessed by magnetic resonance imaging (MRI) in beta thalassemic patients. European Journal of Radiology, Volume 81, Issue 7. p1465– 1470
9. Yamamura, Jin & Pfeifer, Charlotte & Schonnagel, Bjorn & Karul, Murat & Jarisch, Andrea & Grosse, Regine & Janka, Gritta & Adam, Gerhard & Nielsen, Peter & DiplPhys, Roland. (2012). Pancreatic Iron Measurement Using MRI-R2\* in Patients with Iron Overload and Thalassemia.
10. Taher, A.T., Musallam, K.M., Cappellini, M.D. (2021). β-Thalassemias. N Engl J Med. 2021 Feb 25;384(8):727-743. doi: 10.1056/NEJMra2021838
11. Farmakis, D., Porter, J., Taher, A., Domenica Cappellini, M., Angastinotis, M., Eleftheriou, A. (2022).Thalassaemia International Federation Guidelines for the Management of Transfusion-dependent Thalassemia. Hemosphere. 2022 Jul 29;6(8):e732.doi: 10.1097/HS9.0000000000000732
12. Colah, R., Gorakshakar, A. & Nadkami, A. (2010). Global Burden, distribution and prevention of Beta-Thalassemia and hemoglobin E disorders. In: 3, ed. Expert Reviae of Hematology. s.l.:s.n
13. Higgs, D. R. 2013. The molecular basis of alpha-thalassemia. In: s.l.:s.n
14. Jalil, T., Yousafzai, Y.M., Rashid, I., Ahmed, S., Ali, A., Fatima, S., Ahmed, J. (2019). Mutational Analysis Of Beta Thalassaemia By Multiplex Arms-Pcr In Khyber Pakhtunkhwa, Pakistan. J Ayub Med Coll Abbottabad. 2019 Jan;31(1):98-103



Jastiniotis, M., Lobitz, S. (2019) Thalassemias: An Overview. Int J Neonatal

Screen. 2019 Mar 20;5(1):16. doi: 10.3390/ijns5010016.

16. Helmi, N., Bashir, M., Shireen, A. & Ahmed, I. M., (2017). Thalassemia review: features, dental considerations and management. *Electronic physician*.
  17. Weatherall, D. J. & Clegg, J. B., (2008). *The thalassemia syndromes*. John Wiley & Sons.
  18. Lokeshwar, M.R., Shah, N.K., Agarwal, B.R., Mangani, M.V., Sachdeva, A. (2016). *Textbook of Hematology and Hemato-Oncology*. The Health Sciences Publisher
  19. Galanello, R. & Origa, R., (2010). Beta-thalassemia. *Orphanet Journal of Rare Disease*.
  20. Rujito, L., (2019). *Thalassemia: genetik Dasar dan Pengelolaan terkini*. Purwokerto: Penerbit Universitas Jenderal Soedirman
  21. Papavasiliou, C., Cambouris, T. & Fessas, P. (1989). *Radiology of Thalassemia*. Verlag Berlin Heidelberg: Springer.
  22. McDowell, L. A., Kudaravalli, P. & Sticco, K. L. (2022). *Iron Overload*. NCBI
  23. Knovich, M.A., Storey, J.A., Coffman, L.G., Torti, S.V., Torti, F.M., (2009). Ferritin for the clinician. *Blood Rev.* 2009 May;23(3):95-104. doi: 10.1016/j.blre.2008.08.001. Epub 2008 Oct 2.
  24. Wood, J.C. (2014). Use of magnetic resonance imaging to monitor iron overload. *Hematol Oncol Clin North Am.* 2014 Aug;28(4):747-64, vii. doi: 10.1016/j.hoc.2014.04.002.
-  iba, A. N. et al. (2017). Serum ferritin values between 300 and 800 ng/mL in

- nontransfusion-dependent thalassemia: A probability curve to guide clinical decision making when MRI is unavailable. American journal oh hematology.
26. Cappellini, M. D. et al. (2014). Guidelines for the management of transfusion dependent thalassemia (TDT). Nicosia, Cyprus: Thalassemia International federation.
  27. Taher, A. T. & Saliba, A. N. (2017). Iron overload in thalassemia: different organs at different rates. Hematology. the American Society og Hematology Education Program Book.
  28. Argyropoulou, M.I., Astrakas, L. (2007). MRI evaluation of tissue iron burden in patients with beta-thalassaemia major. Pediatr Radiol. 2007 Dec;37(12):1191-200; quiz 1308-9. doi: 10.1007/s00247-007-0567-1. Epub 2007 Aug 21.
  29. Gandon, Y., Olivie, D., Guyader, D. et al. (2004). Non-invasive assessment of hepatic iron stores by MRI. Lancet 363:357–362
  30. St Pierre, T.G., Clark, P.R., Chua-anusorn, W et al. (2005). Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 105:855–861
  31. Huang, J., Shen, J., Yang, Q., Cheng, Z., Chen, X., Yu, T., Zhong, J., Su, Y., Guo, H., Liang, B. (2021) Quantification of pancreatic iron overload and fat infiltration and their correlation with glucose disturbance in pediatric thalassemia major patients. Quant Imaging Med Surg 2021;11(2):665-675. doi: 10.21037/qims-20-292
  32. Habib, R.M, El-Sayed Ayad, R.G. (2021). Assessment of hepatic and pancreatic iron overload by magnetic resonance in  $\beta$ -thalassemia major. noufia Med J 2021;34:1410-5



33. Noetzli, L.J., Papudesi, J., Coates, T.D., Wood, J.C. (2009). Pancreatic iron loading predicts cardiac iron loading in thalassemia major. *Blood*. 2009 Nov 5;114(19):4021-6. doi: 10.1182/blood-2009-06-225615.
34. Meloni, A., Positano, V., Pistoia, L. et al. (2022). Pancreatic iron quantification with MR imaging: a practical guide. *Abdom Radiol* 47, 2397–2407. <https://doi.org/10.1007/s00261-022-03552-y>
35. Rasel, M. & Mahboobi, S., (2023). Continuing Education Activity. Statpearls
36. Casale, M. et al., (2019). Predicting factors for liver iron overload at the first magnetic resonance in children with thalassaemia major. *Blood Transfusion*, p. 165–170.
37. Darvishi-Khezri, H. et al. (2022). Ferritin thresholds for cardiac and liver hemosiderosis in  $\beta$ -thalassemia patients: a diagnostic accuracy study. *Sci Rep.*
38. Ibrahim, A. S., El-Fatah, A. H. A., El-Halim, A. F. A. & Mohamed, F. F. (2023). Serum Ferritin Levels and Other Associated Parameters with Diabetes Mellitus in Adult Patients Suffering from Beta Thalassemia Major. *J Blood Med.*
39. Riaz, H. et al. (2011). Serum ferritin levels, socio-demographic factors and desferrioxamine therapy in multi-transfused thalassemia major patients at a government tertiary care hospital of Karachi, Pakistan. s.l.:BMC.
40. Leechanroenkiet, K., Lithanatudom, P., Sornjai, W. & Smith, D. R. (2016). Iron Dysregulation in beta-thalassemia. *Asian Pacific Journal of Tropical Medicine*.



41. Bhalodiya, V. R., Valiya, L. G., Niyati, A. M. & Phadariya, B. B. (2023). Correlation of serum ferritin level in transfusion-dependant thalassemia major patients: a study at a medical college affiliated hospital in Gujarat region. s.l.:International Journal of Contemporary Pediatrics.
42. Taher, A. et al. (2008). Correlation of liver iron concentration determined by R2 magnetic resonance imaging with serum ferritin in patients with thalassemia intermedia. s.l.:haematologica.



## Lampiran

### Lampiran 1. Ethical Clearance



KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI  
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN  
KOMITE ETIK PENELITIAN UNIVERSITAS HASANUDDIN  
RSPTN UNIVERSITAS HASANUDDIN  
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR.  
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu  
JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.  
Contact Person: dr. Agus Salim Bukhari.,MMed.PhD, SpGK TELP. 081241850858, 0411 5780103, Fax : 0411-581431



#### REKOMENDASI PERSETUJUAN ETIK

Nomor : 234/UN4.6.4.5.31/ PP36/ 2024

Tanggal: 4 April 2024

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH24030196	No Sponsor	
Peneliti Utama	dr. Resty Dwi Umiati	Sponsor	
Judul Penelitian	HUBUNGAN ANTARA KADAR FERRITIN SERUM DENGAN NILAI R2* PANKreas MENGGUNAKAN MRI 3T PADA PASIEN ANAK DENGAN THALASSEMIAS		
No Versi Protokol	1	Tanggal Versi	25 Maret 2024
No Versi PSP		Tanggal Versi	
Tempat Penelitian	RSUP Dr. Wahidin Sudirohusodo Makassar		
Jenis Review	<input type="checkbox"/> Exempted <input checked="" type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal	Masa Berlaku 4 April 2024 sampai 4 April 2025	Frekuensi review lanjutan
Ketua KEP Universitas Hasanuddin	Prof. dr. Muh Nasrum Massi,PhD,SpMK, Subsp. Bakt(K)	Tanda tangan	
Sekretaris KEP Universitas Hasanuddin	dr. Firdaus Hamid, PhD, SpMK(K)	Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Lapor SUSAR dalam 72 jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari protokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan



## Lampiran 2. Data Statistik Penelitian

### Uji Deskriptif Statistics

Usia

N	Valid	33
	Missing	0

### JenisKelamin

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	Laki-laki	15	45.5	45.5	45.5
	Perempuan	18	54.5	54.5	100.0
	Total	33	100.0	100.0	

### Usia

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	< 5 tahun	6	18.2	18.2	18.2
	5-10 tahun	15	45.5	45.5	63.6
	10-18 tahun	12	36.4	36.4	100.0
	Total	33	100.0	100.0	

### LamaTransfusi

		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	< 5 tahun	16	48.5	48.5	48.5
	> 5 tahun	17	51.5	51.5	100.0
	Total	33	100.0	100.0	

### Case Processing Summary

JenisKelamin	KadarFerritin	Cases					
		Valid		Missing		Total	
		N	Percent	N	Percent	N	Percent
Laki-laki	KadarFerritin	15	100.0%	0	0.0%	15	100.0%
Perempuan		18	100.0%	0	0.0%	18	100.0%

### Descriptives

JenisKelamin		Statistic	Std. Error
KadarFerritin	Laki-laki	Mean	3232.2793
		95% Confidence Interval for Mean	1436.6734
		Lower Bound	5027.8853
		Upper Bound	
		5% Trimmed Mean	3028.9959
		Median	1607.0000
		Variance	10513446.962
		Std. Deviation	3242.44460
		Minimum	399.50
		Maximum	9724.16



	Range	9324.66	
	Interquartile Range	4061.50	
	Skewness	1.108	.580
	Kurtosis	-.108	1.121
Perempuan	Mean	2051.1306	411.43927
	95% Confidence Interval for Mean	Lower Bound Upper Bound	1183.0696 2919.1915
	5% Trimmed Mean	1893.2634	
	Median	1741.8200	
	Variance	3047080.891	
	Std. Deviation	1745.58898	
	Minimum	310.80	
	Maximum	6633.07	
	Range	6322.27	
	Interquartile Range	1927.15	
	Skewness	1.632	.536
	Kurtosis	2.534	1.038

#### Tests of Normality

JenisKelamin	Kolmogorov-Smirnov <sup>a</sup>			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
Laki-laki	.251	15	.012	.808	15	.005
Perempuan	.206	18	.041	.815	18	.002

a. Lilliefors Significance Correction

#### Case Processing Summary

Usia	Cases						
	Valid		Missing		Total		
	N	Percent	N	Percent	N	Percent	
KadarFerritin	< 5 tahun	6	100.0%	0	0.0%	6	100.0%
	5-10 tahun	15	100.0%	0	0.0%	15	100.0%
	10-18 tahun	12	100.0%	0	0.0%	12	100.0%

#### Descriptives

Usia	Statistic	Std. Error
KadarFerritin	Mean	1710.3417
	95% Confidence Interval for Mean	Lower Bound Upper Bound
		202.4443 3218.2391
	5% Trimmed Mean	1636.3574
	Median	1209.2850
	Variance	2064581.218
	Std. Deviation	1436.86507
	Minimum	555.30
	Maximum	4197.10
	Range	3641.80
	Interquartile Range	2274.64



	Skewness		1.200	.845
	Kurtosis		.788	1.741
5-10 tahun	Mean		2625.3120	700.22212
	95% Confidence Interval for Mean	Lower Bound Upper Bound	1123.4849 4127.1391	
	5% Trimmed Mean		2357.1267	
	Median		1607.0000	
	Variance		7354665.198	
	Std. Deviation		2711.94860	
	Minimum		353.80	
	Maximum		9724.16	
	Range		9370.36	
	Interquartile Range		2249.75	
	Skewness		1.680	.580
	Kurtosis		2.327	1.121
10-18 tahun	Mean		2980.2342	828.59049
	95% Confidence Interval for Mean	Lower Bound Upper Bound	1156.5188 4803.9495	
	5% Trimmed Mean		2784.7046	
	Median		1770.7550	
	Variance		8238746.426	
	Std. Deviation		2870.32166	
	Minimum		310.80	
	Maximum		9169.20	
	Range		8858.40	
	Interquartile Range		3496.91	
	Skewness		1.317	.637
	Kurtosis		.786	1.232

#### Tests of Normality

Usia	Kolmogorov-Smirnov <sup>a</sup>			Shapiro-Wilk			
	Statistic	df	Sig.	Statistic	df	Sig.	
KadarFerritin	< 5 tahun	.267	6	.200*	.842	6	.136
	5-10 tahun	.263	15	.006	.781	15	.002
	10-18 tahun	.241	12	.052	.831	12	.021

\*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

#### Case Processing Summary

LamaTransfusi	Cases					
	Valid		Missing		Total	
	N	Percent	N	Percent	N	Percent
< 5 tahun	16	100.0%	0	0.0%	16	100.0%
> 5 tahun	17	100.0%	0	0.0%	17	100.0%

#### Descriptives

LamaTransfusi	Statistic	Std. Error
---------------	-----------	------------



KadarFerritin	< 5 tahun	Mean	2223.0506	563.02647
		95% Confidence Interval for Mean	Lower Bound Upper Bound	1022.9881 3423.1131
		5% Trimmed Mean		1898.9751
		Median		1680.6650
		Variance		5071980.820
		Std. Deviation		2252.10586
		Minimum		555.30
	> 5 tahun	Maximum		9724.16
		Range		9168.86
		Interquartile Range		2042.32
		Skewness		2.725 .564
		Kurtosis		8.741 1.091
		Mean		2931.5135 691.82846
		95% Confidence Interval for Mean	Lower Bound Upper Bound	1464.9027 4398.1244
		5% Trimmed Mean		2730.5706
		Median		1729.3100
		Variance		8136652.601
		Std. Deviation		2852.48183
		Minimum		310.80
		Maximum		9169.20
		Range		8858.40
		Interquartile Range		4639.08
		Skewness		1.014 .550
		Kurtosis		-.226 1.063

#### Tests of Normality

LamaTransfusi	Kolmogorov-Smirnov <sup>a</sup>			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
KadarFerritin	.260	16	.005	.685	16	.000
	.241	17	.010	.842	17	.008

a. Lilliefors Significance Correction

#### Case Processing Summary

NilaiR2pankreas	JenisKelamin	Cases					
		Valid		Missing		Total	
		N	Percent	N	Percent	N	Percent
Laki-laki	JenisKelamin	15	100.0%	0	0.0%	15	100.0%
		18	100.0%	0	0.0%	18	100.0%

#### Descriptives

JenisKeluarga	JenisKelamin	Descriptives			Statistic	Std. Error		
		Mean						
		95% Confidence Interval for Mean	Lower Bound	Upper Bound				
Wanita	Laki-laki	240.5333	83.29910	61.8745	419.1921			

	5% Trimmed Mean	215.1667	
	Median	72.3333	
	Variance	104081.092	
	Std. Deviation	322.61601	
	Minimum	42.33	
	Maximum	895.33	
	Range	853.00	
	Interquartile Range	135.00	
	Skewness	1.605	.580
	Kurtosis	.799	1.121
Perempuan	Mean	86.2222	15.15646
	95% Confidence Interval for Mean	Lower Bound Upper Bound	54.2449 118.1996
	5% Trimmed Mean	79.5247	
	Median	64.5000	
	Variance	4134.928	
	Std. Deviation	64.30341	
	Minimum	.00	
	Maximum	293.00	
	Range	293.00	
	Interquartile Range	34.67	
	Skewness	2.120	.536
	Kurtosis	5.916	1.038

#### Tests of Normality

JenisKelamin	Kolmogorov-Smirnov <sup>a</sup>			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
Laki-laki	.360	15	.000	.603	15	.000
Perempuan	.279	18	.001	.779	18	.001

a. Lilliefors Significance Correction

#### Case Processing Summary

Usia	Cases					
	Valid		Missing		Total	
	N	Percent	N	Percent	N	Percent
< 5 tahun	6	100.0%	0	0.0%	6	100.0%
5-10 tahun	15	100.0%	0	0.0%	15	100.0%
10-18 tahun	12	100.0%	0	0.0%	12	100.0%

#### Descriptives

Usia	Statistic	Std. Error
ankreas < 5 tahun	Mean	65.2778
	95% Confidence Interval for Mean	Lower Bound Upper Bound
		53.2016 77.3540
	5% Trimmed Mean	64.9938
	Median	63.5000

	Variance	132.419	
	Std. Deviation	11.50732	
	Minimum	53.33	
	Maximum	82.33	
	Range	29.00	
	Interquartile Range	23.00	
	Skewness	.537	.845
	Kurtosis	-1.056	1.741
5-10 tahun	Mean	152.1556	56.36534
	95% Confidence Interval for Mean	Lower Bound Upper Bound	31.2639 273.0472
	5% Trimmed Mean	119.3210	
	Median	68.0000	
	Variance	47655.776	
	Std. Deviation	218.30203	
	Minimum	.00	
	Maximum	895.33	
	Range	895.33	
	Interquartile Range	94.33	
	Skewness	3.197	.580
	Kurtosis	11.065	1.121
10-18 tahun	Mean	207.1667	85.87315
	95% Confidence Interval for Mean	Lower Bound Upper Bound	18.1611 396.1722
	5% Trimmed Mean	180.3889	
	Median	73.1667	
	Variance	88490.374	
	Std. Deviation	297.47332	
	Minimum	35.67	
	Maximum	860.67	
	Range	825.00	
	Interquartile Range	108.75	
	Skewness	1.981	.637
	Kurtosis	2.460	1.232

#### Tests of Normality

Usia	Kolmogorov-Smirnov <sup>a</sup>			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
NilaiR2pankreas						
< 5 tahun	.211	6	.200*	.916	6	.478
5-10 tahun	.291	15	.001	.561	15	.000
10-18 tahun	.362	12	.000	.577	12	.000

a lower bound of the true significance.  
\*Significance Correction



#### Case Processing Summary

LamaTransfusi	Cases
---------------	-------

		Valid		Missing		Total	
		N	Percent	N	Percent	N	Percent
NilaiR2pankreas	< 5 tahun	16	100.0%	0	0.0%	16	100.0%
	> 5 tahun	17	100.0%	0	0.0%	17	100.0%

#### Descriptives

	LamaTransfusi			Statistic	Std. Error
		Mean	SD		
NilaiR2pankreas	< 5 tahun	129.1250	53.27056		
		15.5815			
		242.6685			
		93.7315			
		66.8333			
		45404.043			
		213.08224			
		.00			
		895.33			
		895.33			
		19.00			
		3.535	.564		
		13.007	1.091		
	> 5 tahun	182.0000	61.18166		
		52.3007			
		311.6993			
		152.4259			
		77.6667			
		63634.333			
		252.25847			
		35.67			
		860.67			
		825.00			
		109.67			
		2.413	.550		
		4.780	1.063		

#### Tests of Normality

	LamaTransfusi	Kolmogorov-Smirnov <sup>a</sup>			Shapiro-Wilk		
		Statistic	df	Sig.	Statistic	df	Sig.
NilaiR2pankreas	< 5 tahun	.455	16	.000	.439	16	.000
	> 5 tahun	.354	17	.000	.565	17	.000

a. Lilliefors Significance Correction

#### Ranks

	JenisKelamin	N	Mean Rank	Sum of Ranks
ritin	Laki-laki	15	17.87	268.00
	Perempuan	18	16.28	293.00

Total	33	
-------	----	--

**Test Statistics<sup>a</sup>**

	KadarFerritin
Mann-Whitney U	122.000
Wilcoxon W	293.000
Z	-.470
Asymp. Sig. (2-tailed)	.638
Exact Sig. [2*(1-tailed Sig.)]	.656 <sup>b</sup>

a. Grouping Variable: JenisKelamin

b. Not corrected for ties.

**Ranks**

	LamaTransfusi	N	Mean Rank	Sum of Ranks
KadarFerritin	< 5 tahun	16	16.75	268.00
	> 5 tahun	17	17.24	293.00
	Total	33		

**Test Statistics<sup>a</sup>**

	KadarFerritin
Mann-Whitney U	132.000
Wilcoxon W	268.000
Z	-.144
Asymp. Sig. (2-tailed)	.885
Exact Sig. [2*(1-tailed Sig.)]	.901 <sup>b</sup>

a. Grouping Variable: LamaTransfusi

b. Not corrected for ties.

**Ranks**

	Usia	N	Mean Rank
KadarFerritin	< 5 tahun	6	14.67
	5-10 tahun	15	16.93
	10-18 tahun	12	18.25
	Total	33	

**Test Statistics<sup>a,b</sup>**

	KadarFerritin
Chi-Square	.551
df	2
Asymp. Sig.	.759

a. Kruskal Wallis Test

b. Grouping Variable: Usia



**Ranks**

	LamaTransfusi	N	Mean Rank	Sum of Ranks
Kankreas	< 5 tahun	16	15.72	251.50
	> 5 tahun	17	18.21	309.50
	Total	33		

### Test Statistics<sup>a</sup>

	NilaiR2pankreas
Mann-Whitney U	115.500
Wilcoxon W	251.500
Z	-.739
Asymp. Sig. (2-tailed)	.460
Exact Sig. [2*(1-tailed Sig.)]	.465 <sup>b</sup>

a. Grouping Variable: LamaTransfusi

b. Not corrected for ties.

### Ranks

	JenisKelamin	N	Mean Rank	Sum of Ranks
NilaiR2pankreas	Laki-laki	15	19.50	292.50
	Perempuan	18	14.92	268.50
	Total	33		

### Test Statistics<sup>a</sup>

	NilaiR2pankreas
Mann-Whitney U	97.500
Wilcoxon W	268.500
Z	-1.356
Asymp. Sig. (2-tailed)	.175
Exact Sig. [2*(1-tailed Sig.)]	.178 <sup>b</sup>

a. Grouping Variable: JenisKelamin

b. Not corrected for ties.

### Ranks

	Usia	N	Mean Rank
NilaiR2pankreas	< 5 tahun	6	12.67
	5-10 tahun	15	17.97
	10-18 tahun	12	17.96
	Total	33	

### Test Statistics<sup>a,b</sup>

	NilaiR2pankreas
Chi-Square	1.474
df	2
Asymp. Sig.	.479

a. Kruskal Wallis Test

b. Grouping Variable: Usia


### Correlations

n's rho	KadarFerritin	Correlation Coefficient	KadarFerritin n	NilaiR2pankreas
			1.000	.647**



	Sig. (2-tailed)	.	.000
N		33	33
NilaiR2pankreas	Correlation Coefficient	.647**	1.000
	Sig. (2-tailed)	.000	.
N		33	33

\*\*. Correlation is significant at the 0.01 level (2-tailed).



### Lampiran 3. Curriculum Vitae

#### CURRICULUM VITAE

##### A. Data Pribadi

- Nama : dr. Resty Dwi Umiati
  - Agama : Islam
  - Tempat/Tgl Lahir : Mapane Poso Pesisir / 19 Maret 1987
  - Alamat : Jl. Gunung Latimojong, Kel. Tampumia Radda, Kec. Belopa, Kab. Luwu, Sulawesi Selatan
- |  |   |
|--|---|
|  | ama Ayah/Ibu : dr. H. Mansyur Djamaruddin / Hj. Yarnis Nur, SE<br>uami : Agussalim, SKM<br>anak : Muhammad Aryandra Rafisqy |
|--|---|



B. Riwayat Pendidikan

- SD : SD Negeri Pembina Tolitoli, lulus tahun 1998
- SMP : SMP Negeri 1 Tolitoli, lulus tahun 2001
- SMA : SMA Negeri 1 Makassar, lulus tahun 20004
- Perguruan Tinggi : Fakultas Kedokteran Universitas Hasanuddin Makassar, angkatan tahun 2004
- Profesi Dokter : Fakultas Kedokteran Universitas Hasanuddin Makassar, lulus tahun 2019
- PPDS : Departemen Radiologi Fakultas Kedokteran Universitas Hasanuddin, Periode Januari 2020

C. Riwayat Pekerjaan

1. Dokter Umum RSUD Batara Guru Belopa
2. Dokter Umum Puskesmas Walenrang Barat
3. Dokter Umum RS. Hikmah Sejahtera Belopa

D. Makalah pada Seminar/Konferensi Ilmiah Nasional :

“Mayer-Rokitansky-Kuster-Hauser Syndrome” : A Case Report, dibawakan pada acara The 3rd Annual Scientific Meeting Indonesian Woman Imaging Society, 02-04 Maret 2023

